Pacira BioSciences Inc (PCRX)’s financial ratios: A comprehensive overview

After finishing at $27.89 in the prior trading day, Pacira BioSciences Inc (NASDAQ: PCRX) closed at $27.67, down -0.79%. In other words, the price has decreased by -$0.22 from its previous closing price. On the day, 554026 shares were traded. PCRX stock price reached its highest trading level at $28.44 during the session, while it also had its lowest trading level at $27.42.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.



Our goal is to gain a better understanding of PCRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.87. For the most recent quarter (mrq), Quick Ratio is recorded 3.74 and its Current Ratio is at 4.78. In the meantime, Its Debt-to-Equity ratio is 0.71 whereas as Long-Term Debt/Eq ratio is at 0.69.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 02 when WINSTON ROY sold 509 shares for $34.88 per share. The transaction valued at 17,751 led to the insider holds 52,440 shares of the business.

Riker Lauren Bullaro sold 643 shares of PCRX for $25,019 on Jul 05. The Senior Vice President, Finance now owns 22,687 shares after completing the transaction at $38.91 per share. On Jun 14, another insider, Riker Lauren Bullaro, who serves as the Senior Vice President, Finance of the company, sold 6,366 shares for $38.42 each. As a result, the insider received 244,606 and left with 22,687 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1.30B and an Enterprise Value of 1.65B. As of this moment, Pacira’s Price-to-Earnings (P/E) ratio for their current fiscal year is 355.20, and their Forward P/E ratio for the next fiscal year is 7.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 30.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.93 while its Price-to-Book (P/B) ratio in mrq is 1.54. Its current Enterprise Value per Revenue stands at 2.48 whereas that against EBITDA is 13.57.

Stock Price History:

Over the past 52 weeks, PCRX has reached a high of $50.11, while it has fallen to a 52-week low of $26.59. The 50-Day Moving Average of the stock is 30.21, while the 200-Day Moving Average is calculated to be 37.37.

Shares Statistics:

The stock has traded on average 497.28K shares per day over the past 3-months and 588.81k shares per day over the last 10 days, according to various share statistics. A total of 45.93M shares are outstanding, with a floating share count of 45.11M. Insiders hold about 2.86% of the company’s shares, while institutions hold 104.16% stake in the company. Shares short for PCRX as of Oct 30, 2023 were 3.59M with a Short Ratio of 3.59M, compared to 3.51M on Sep 28, 2023. Therefore, it implies a Short% of Shares Outstanding of 7.72% and a Short% of Float of 10.77%.

Earnings Estimates

Its stock is currently analyzed by Catalyst Pharmaceuticals, Inc. different market analysts. The consensus estimate for the next quarter is $5.40, with high estimates of $14.36 and low estimates of $0.50.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular